Roche Holding 관리

관리 기준 확인 2/4

Roche Holding CEO는 Thomas Schinecker, Mar2023 에 임명되었습니다 의 임기는 1.75 년입니다. 는 CHF 906.50K 가치에 해당하는 회사 주식의 0% 직접 소유합니다. 906.50K. 경영진과 이사회의 평균 재임 기간은 각각 4.9 년과 7.8 년입니다.

주요 정보

Thomas Schinecker

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.8yrs
CEO 소유권	0.0004%
경영진 평균 재임 기간	4.9yrs
이사회 평균 재임 기간	7.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Thomas Schinecker 의 보수는 Roche Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CHF 11b
Mar 31 2024	n/a	n/a	CHF 11b
Dec 31 2023	n/a	n/a	CHF 11b
Sep 30 2023	n/a	n/a	CHF 11b
Jun 30 2023	n/a	n/a	CHF 11b
Mar 31 2023	n/a	n/a	CHF 12b
Dec 31 2022	CHF 5m	CHF 1m	CHF 12b
Sep 30 2022	n/a	n/a	CHF 14b
Jun 30 2022	n/a	n/a	CHF 15b
Mar 31 2022	n/a	n/a	CHF 14b
Dec 31 2021	CHF 4m	CHF 1m	CHF 14b
Sep 30 2021	n/a	n/a	CHF 14b
Jun 30 2021	n/a	n/a	CHF 14b
Mar 31 2021	n/a	n/a	CHF 14b
Dec 31 2020	CHF 4m	CHF 879k	CHF 14b
Sep 30 2020	n/a	n/a	CHF 14b
Jun 30 2020	n/a	n/a	CHF 13b
Mar 31 2020	n/a	n/a	CHF 13b
Dec 31 2019	CHF 2m	CHF 609k	CHF 13b

보상 대 시장: Swiss 시장에서 비슷한 규모의 회사에 비해 Thomas 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Thomas 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Thomas Schinecker (49 yo)

1.8yrs

테뉴어

CHF 5,335,592

보상

Dr. Thomas Schinecker serves as Chairman of the Board at Genentech, Inc. since March 2023. He serves as Chief Executive Officer at Roche Holding AG since March 15, 2023. He has been Chief Executive Officer...

리더십 팀

이름	위치	테뉴어	보상	소유권
Severin Schwan	Executive Chairman	11.8yrs	CHF 11.48m	0.043% CHF 86.6m
Thomas Schinecker	Chief Executive Officer	1.8yrs	CHF 5.34m	0.00045% CHF 906.5k
Alan Hippe	Chief Financial & Information Officer	13.7yrs	CHF 6.05m	0.0063% CHF 12.7m
Bruno Eschli	Head of Investor Relations	no data	데이터 없음	데이터 없음
Claudia Bockstiegel	General Counsel	4.7yrs	데이터 없음	데이터 없음
Pascale Schmidt	Chief Compliance Officer	4.9yrs	데이터 없음	데이터 없음
Barbara Schadler	Head of Group Communications	5.2yrs	데이터 없음	데이터 없음
Cristina Wilbur	Chief People Officer	8.8yrs	CHF 4.25m	0.0020% CHF 4.0m
Nicolas Dunant	Head of Group Media Relations	no data	데이터 없음	데이터 없음
Boris Zaitra	Head of Corporate Business Development	no data	데이터 없음	데이터 없음
Paulo Fontoura	Head of Neuroscience Clinical Development	no data	데이터 없음	데이터 없음
Johannes Clevers	Head of Roche Pharma Research & Early Development	2.8yrs	CHF 82.50k	데이터 없음

4.9yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: RO 의 관리팀은 경험 ( 4.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Severin Schwan	Executive Chairman	11.8yrs	CHF 11.48m	0.043% CHF 86.6m
Bernard Poussot	Non-Executive Independent Director	9.9yrs	CHF 330.00k	0.00013% CHF 261.9k
Ulf Schneider	Director	1.8yrs	데이터 없음	0.00063% CHF 1.3m
Andre Hoffmann	Independent Vice Chairman	28.9yrs	CHF 402.82k	3.53% CHF 7.1b
Patrick Frost	Independent Non Executive Director	4.8yrs	CHF 360.00k	0.00025% CHF 503.6k
Richard Lifton	Non-Executive Independent Director	9.9yrs	CHF 346.71k	0% CHF 0
Anita Hauser	Non-Executive Independent Director	7.8yrs	CHF 336.16k	0.00040% CHF 805.8k
Jorg Duschmale	Non-Executive Independent Director	4.8yrs	CHF 364.59k	데이터 없음
Akiko Iwasaki	Director	1.8yrs	데이터 없음	데이터 없음
Claudia Ricarda Suessmuth Dyckerhoff	Non-Executive Independent Director	8.8yrs	CHF 367.02k	0.00034% CHF 684.9k
Jemilah Mahmood	Independent Non-Executive Director	2.8yrs	CHF 272.50k	데이터 없음

7.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: RO 의 이사회는 경험(평균 재직 기간 7.8 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 22:40
장 마감 주가	2024/12/23 00:00
수익	2024/06/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Roche Holding AG 59 애널리스트 중 16 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Kamla Singh	AlphaValue
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research

Roche Holding 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Roche Announces Management and Board Committee Changes

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Recent updates

Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions

New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma

Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령